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ABSTRACT: Microcephalin-1 (MCPH1) exists as 2 isoforms that regulate cyclin-dependent kinase-1 activation and
chromosome condensationduringmitosis,withMCPH1mutations causingprimarymicrocephaly.MCPH1 is also a
tumor suppressor protein, with roles in DNA damage repair/checkpoints. Despite these important roles, there is
little informationon the cellular regulationofMCPH1.WeshowthatbothMCPH1 isoformsarephosphorylated in a
cyclin-dependent kinase-1–dependent manner in mitosis and identify several novel phosphorylation sites. Upon
mitotic exit, MCPH1 isoforms were degraded by the anaphase-promoting complex/cyclosome–CDH1 E3 ligase
complex. Anaphase-promoting complex/cyclosome–CDH1 target proteins generally have D-Box or KEN-Box
degron sequences.We found thatMCPH1 isoforms aredegraded independently,with the long isoformdegradation
beingD-Box dependent, whereas the short isoformwasKEN-Box dependent. Our research identifies several novel
mechanisms regulatingMCPH1 and also highlights important issues with several commercialMCPH1 antibodies,
withpotential relevance topreviouslypublisheddata.—Meyer, S.K.,Dunn,M.,Vidler,D. S., Porter,A., Blain, P.G.,
Jowsey, P. A. Phosphorylation of MCPH1 isoforms during mitosis followed by isoform-specific degradation by
APC/C-CDH1. FASEB J. 33, 000–000 (2019). www.fasebj.org
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Mutations in microcephalin-1 (MCPH1) cause primary
microcephaly, a rare genetic syndrome associated with a
significantly reduced cerebral cortex and mental re-
tardation (1, 2). Analysis of cells from affected individuals
revealed a striking premature chromosome condensation
(PCC) phenotype, characterized by an increased number
of prophase-like cells (PLCs) with condensed chromatin
and an intact nuclear membrane but lacking histone H3
Ser10 phosphorylation, a marker for mitotic cells (3–5).
Interestingly, this phenotype was corrected by depletion
of condensin II subunits (6). Subsequent studies revealed
that MCPH1 was able to bind the condensin II complex
directly and also to bind mitotic chromatin, effectively
competing with and blocking the binding of condensin II
(7, 8). Current models suggest that in the absence of
MCPH1, condensin II is able to bind to chromatin and
promote condensation before the onset of mitosis. Several
studies have shown that cells lacking MCPH1 undergo
chromatin condensation in theG2phase of the cell cycle.A
recent study found that inhibition of cyclin-dependent
kinase-1 (CDK1) in MCPH1-deficient cells significantly
reduced the proportion of cells with prematurely con-
densed chromatin (9). This finding supports other research
showing that CDK1 is prematurely activated in cells
lacking MCPH1, with CDK1 hypophosphorylation on
Tyr15 apparent as soon as 2–4 h after release from S-phase
synchronization (3). In addition, an elegant studyusing an
MCPH1 knockout mouse revealed premature CDK1 ac-
tivation inneuroprogenitor cells, due tomis-localizationof
checkpoint kinase 1 (CHK1) andactivation of theCDC25B
phosphatase (10). This scenario, in turn, caused spindle
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misalignment and a switch in the mode of cell division
from symmetric to asymmetric, thus reducing the pool of
neuroprogenitor cells in the developing brain.
In addition to being a key regulator of CDK1 activation
and chromatin condensation during mitosis, MCPH1 is a
tumor suppressor protein. Down-regulation and/or mu-
tation of MCPH1 have been reported in breast, ovarian,
colorectal, gastric, and colon cancer (11–14), and multiple
studieshaveshown thatMCPH1-deficient cells haveDNA
repair and checkpoint defects (13, 15, 16). MCPH1 is
recruited to DNA double-strand breaks via phosphory-
lated histone H2AX and subsequently helps recruit
BRCA2 (and thus RAD51), promoting homologous re-
combination repair (HRR) (17, 18). Cells lacking MCPH1
exhibit sensitivity to ionizing radiation and defects in the
S-phase and G2/M checkpoints (15).
MCPH1 contains an N-terminal BRCT (BRCA1 C-
terminal) domain and 2 C-terminal BRCT domains.
The latter are required for recruitment to DNA dam-
age foci via binding to phosphorylated histone H2AX
(Ser139), whereas the N-terminal domain is believed
to be involved in chromatin binding and the regula-
tion of chromosome condensation. MCPH1 exists as 2
major isoforms: a long isoform (MCPH1-L) contain-
ing all 3 BRCT domains and a short isoform (MCPH1-
S) produced via a splicing-inserted stop codon, which
eliminates both C-terminal BRCT domains (19). Studies
suggest that both isoforms contribute to chromosome
condensation, whereas the DNA damage roles of MCPH1
are believed to predominantly involve the long isoform,
highlighting the importance of the C-terminal BRCT do-
main pair. Although other isoforms have been reported,
the biologic significance of these isoforms is less clear.
Despite the important cellular roles of both MCPH1
isoforms, little information is available regarding their
cellular regulation. An earlier study suggested that
MCPH1 was not cell cycle regulated, with no apparent
change in abundance or gel migration pattern in cell syn-
chronization experiments (17). More recently, Drosophila
MCPH1 was shown to be regulated by the anaphase-
promoting complex/cyclosome (APC/C), although the
same study suggested that human MCPH1 was not sim-
ilarly regulated (20). The APC/C is an E3 ubiquitin ligase
that drives the metaphase–anaphase transition and is ac-
tivated by binding to either CDC20 or CDH1 (21, 22). The
former targets proteins during the metaphase–anaphase
transition, before being replaced by CDH1 during late
mitosis and G1, changing the substrate specificity of the
APC/C. CDC20 and CDH1 generally recognize target
proteins via specific degron sequences, called D-Box
(minimal consensus of RxxL) and KEN-Box. A recent
study showed that the long isoform of human MCPH1
could be targeted by theAPC/C–CDH1 complex, although
the kinetics of apparent degradation did not align with
APC/C–CDH1 activation, with decreased MCPH1 levels
observedbeforecyclinB1degradation(aCDC20target) (23).
These findings are likelydue to theparticular antibodyused
and are addressed as part of the present study.
The present study aimed to clarify some of the con-
flicting findings in the literature regarding the cell
cycle–dependent regulation ofMCPH1. After thorough
characterization of commercial antibodies, we were
able to clearly showCDK1-dependent phosphorylation
of both MCPH1 isoforms during mitosis, followed
by APC/C–CDH1–dependent degradation in the G1
phase. Our data show that 1 commercial antibody is
blocked from binding phosphorylated MCPH1, with
potential relevance to previously published studies.
Using mass spectrometry, we identified several novel
phosphorylation sites in MCPH1 purified from mitotic
cells, including 2 that were within/near a functionally
relevant D-Box. Interestingly, although both MCPH1
isoforms were regulated by APC/C–CDH1, this regula-
tion involved different degron sequences. Two function-
ally important degron sequences were identified within
MCPH1-L. The first sequence is a C-terminal D-Box
(amino acids 752–755), which is necessary for CDH1-
dependent degradation of MCPH1-L. The second se-
quence is a KEN-Box sequence (amino acids 599–601),
the mutation of which markedly reduced the interaction
between MCPH1-L and CDH1 but had no effect on
CDH1-mediated degradation of MCPH1-L. The func-
tional significance of theKEN-Box–dependent interaction
between MCPH1-L and CDH1 remains to be elucidated.
Interestingly, this sameKEN-Boxwas found tocontrol the
CDH1-dependent degradation of the MCPH1-S isoform.
MATERIALS AND METHODS
Cell lines, chemicals, and treatments
HEK293,A549, U2OS, andHeLa cellswere obtained fromPublic
Health England (PHE) Culture Collections (Salisbury, United
Kingdom).HeLaTet-On cellswere obtained fromThermoFisher
Scientific (Waltham, MA, USA). All cells were maintained as
exponentially growing cultures in DMEM supplemented with
10% fetal bovine serum and 2 mM L-glutamine. Nocodazole,
L-mimosine, cycloheximide, and tetracyclinewere obtained from
MilliporeSigma (Burlington, MA, USA), RO3306 (CDK1 in-
hibitor) from Tocris Bioscience (Minneapolis, MN, USA), and
ProTAME (APC/C inhibitor) from Bio-Techne (Minneapolis,
MN, USA). Stock solutions of all compounds were prepared in
DMSO, except for L-mimosine, which was dissolved in 20 mM
HEPES (pH 7). Compounds were added to cells at the indicated
concentrations (asnoted in the figure legends),withDMSOlevels
being maintained at,0.2% (v/v).
Plasmids, mutagenesis, small interfering RNA,
and transfections
A plasmid encoding human MCPH1-L (full length or long iso-
form) was kindly provided by Professor Shiaw-Yih Lin (MD
Anderson Cancer Center, University of Texas, USA). This plas-
mid was used as a template to subclone MCPH1-L into an ex-
pression plasmid with an N-terminal green fluorescent protein
(GFP) tag (PS100048; OriGene Technologies, Rockville, MD,
USA). Plasmids encoding human CDC20 and CDH1 were
obtained from Dr. Jacques Bertoglio (Institut Gustave Roussy,
Villejuif, France) and used as a template for subcloning of each
into an expression plasmid with an N-terminal FLAG tag
(PS100014; OriGene Technologies). Plasmids encoding
tetracycline-inducible GFP–MCPH1-L and GFP–MCPH1-S were
kindly provided by Professor Andrew Jackson (Edinburgh Uni-
versity, Edinburgh,UnitedKingdom). Fragments ofMCPH1and
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CDH1 were generated by the introduction of stop codons
using site-directed mutagenesis, with the same technique
used to mutate specific D- and KEN-boxes in MCPH1. Site-
directed mutagenesis was performed by using either Phusion
Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher
Scientific) or a QuikChange XL II kit (Stratagene, San Diego,
CA, USA), according to the manufacturer’s instructions. PCR
reactions were subject to Dpn1 digestion before trans-
formation into NEB 10-b competent Escherichia coli cells (New
England Biolabs, Ipswich, MA, USA) and antibiotic selec-
tion on Luria broth (LB) agar plates. Selected clones were an-
alyzed by using Sanger sequencing to confirm mutated DNA
sequences.
For protein interaction studies,HEK293 cellswere transfected
by using calcium phosphate precipitation. Plasmids were trans-
fected into HeLa cells using Lipofectamine 2000 (Thermo Fisher
Scientific), with slight modifications to the manufacturer’s rec-
ommended instructions. For cells plated in 6 cm dishes, 3.5 mg
DNA and 4 ml Lipofectamine 2000 were used (both added to
150 ml serum-free DMEM in separate tubes, before combining in
a single tube). For cotransfection of GFP–MCPH1 (andmutants)
with FLAG/FLAG–CDC20/FLAG–CDH1 inHeLa Tet-On cells,
2.5 mg GFP–MCPH1 and 1 mg FLAG–CDH1 per 6 cm dish were
used, and GFP–MCPH1 expression was induced by adding tet-
racycline 10 ng/ml.
For small interfering RNA (siRNA), the following sequences
were used to target MCPH1: AAAGGAAGTTGGAAG-
GATCCA (Qiagen, Germantown, MD, USA) and SMARTpool
ON-TARGETplus (L-008447-00-0005; Dharmacon, Lafayette,
CO, USA). To target CDH1, SMARTpool ON-TARGETplus
siRNA was used (L-015377-00-0005; Dharmacon). RNA was
transfected into cells (20 nM final concentration) by using
RNAiMAX (Thermo Fisher Scientific) for 48–72 h.
Immunoprecipitation/pull-down, Western blotting,
and antibodies
To investigate the interaction between MCPH1 and CDH1, a
pull-down approach was used. GFP–MCPH1 was immunopre-
cipitated from HEK293 cells before incubation with cell extracts
containing FLAG-tagged CDH1 (or CDH1 fragments). For im-
munoprecipitation of GFP–MCPH1, cells were washed in cold
PBS before lysis in NETN buffer (50 mM Tris pH 7.6, 150 mM
NaCl, 1 mM EDTA, and 1% NP-40) containing protease and
phosphatase inhibitors (MS-SAFE cocktail; MilliporeSigma).
After incubation at 4°C for 15 min, lysates were cleared by cen-
trifugation and supernatants isolated. Cell lysates were in-
cubated with GFP-Trap (Chromotek, Planegg-Martinsried,
Germany) to purify GFP-tagged proteins for 2 h at 4°C before
washing 2 times in TBST (50 mM Tris pH 7.6, 150 mM NaCl,
and 0.2% Tween-20), followed by a wash in NETN. After re-
moval of this supernatant, cell extracts containing FLAG–
CDH1 (prepared inNETNbuffer)were added toGFP–MCPH1
immobilized on GFP–TRAP beads. After incubation for 3 h at
4°C, the beads were washed 3 times in TBST and resuspended
in an equal volume of 23 LDS Sample Buffer (Thermo Fisher
Scientific) containing 5% 2-ME and heated to 70°C for 10 min.
Samples were analyzed by Western blotting using 3–8% Tris
acetate gels (Thermo Fisher Scientific) before transfer to nitro-
cellulose using an iBlot2 machine (Thermo Fisher Scientific)
and antibody incubation (discussed later).
For Western blotting of whole cell extracts, cells were lysed
directly into 23 LDS Sample Buffer containing 2.5% 2-ME,
heated to 70°C for 10min, and sonicated to shear genomic DNA.
Protein electrophoresis was performed by using either 3–8%Tris
acetate or 4–12% bis Tris gels (Thermo Fisher Scientific) before
transferring to nitrocellulose by using an iBlot2 machine. Mem-
branes were blocked in either 5% dried skimmed milk/TBST or
2.5% bovine serum albumin/TBST (depending on the primary
antibody used) for 1 h before overnight incubation in blocking
buffer containing the following primary antibodies: MCPH1
(11962-1-AP;Proteintech, Rosemont, IL,USA),MCPH1 (Ab2612;
Abcam, Cambridge, United Kingdom), CDH1/FZR1 (NBP-
54465; Novus Biologicals, Littleton, CO, USA), and mitotic
(phospho) protein monoclonal-2 (MilliporeSigma). In addition,
the following primary antibodies from Cell Signaling Technol-
ogy (Danvers, MA, USA) were also used: GFP (2956),
glyceraldehyde-3-phosphate dehydrogenase (2118), histone [3H]
phospho-Serine 10 (9701), DYKDDDDK/FLAG tag (2368), cyclin
B1 (4135), phospho-cdc2 Tyr15 (9111), and MCPH1 (4120). After
incubation with the relevant horseradish peroxidase–conjugated
secondary antibody, Western blots were visualized with ECL
Prime (GEHealthcare,Chicago, IL,USA) and images capturedby
using a Syngene (Cambridge, United Kingdom) G:Box gel doc-
umentation system.
Mass spectrometry
HEK293 cells were transfected with GFP–MCPH1 for 24 h using
calcium phosphate before treatment with nocodazole for 20 h.
Mitotic cells were isolated by using the shake-off procedure,
lysed in NETN buffer (as previously described), and GFP–
MCPH1 immunoprecipitatedanddigestedbyusing the iSTGFP-
TRAP kit from Chromotek, according to the manufacturer’s in-
structions. Dried peptides were reconstituted in 25 ml of 95:5
water:acetonitrile 0.1% formic acid. The tryptic digest was ana-
lyzed byusingdata-dependent techniques on a TripleTOF 5600+
high-resolution quadrupole time-of-flight mass spectrometer
(Sciex, Framingham, MA, USA) equipped with a DuoSpray Ion
Source operated in positive electrospray mode, coupled to an
Eksigent NanoLC 420 system (Sciex). Analyst TF v.1.7.1 (Sciex)
was used for instrument control and data acquisition. Chro-
matographic separation was achieved by gradient elution over
95min,withanACEC18 capillary liquidchromatographycolumn
(100 mm 3 300 mm 3 3 mm; Hichrom, Theale, United King-
dom) fitted with a 0.25 mm column saver precolumn filter, us-
ing 0.1% formic acid in water and 0.1% formic acid in
acetonitrile as the mobile phase, at a flow rate of 5 ml/min. A
5 ml injection was used. Data-dependent analysis comprised a
250 ms survey scan, in which the 20 most intense ions were
selected for subsequent automated tandemmass spectrometry
(MS/MS) analysis, with each MS/MS event consisting of a
50ms scan. Ionswere isolatedbyusing aquadrupole resolution
of 0.7 Da and fragmented in the collision cell by using collision
energy ramped from 15 to 45 eVwithin the 50ms accumulation
time. The data-dependent MS/MS data were processed by
using ProteinPilot software version 4.5 (Sciex). Data were
searched against the uniprot_sprot_can+iso database, with
phosphorylation emphasis (https://www.uniprot.org/).
Premature chromosome condensation
U2OS cells were cotransfected with siRNA targeting MCPH1,
or nontargeting control, along with GFP or GFP-tagged
MCPH1 (siRNA resistant) using Lipofectamine 2000. After
72 h, cells were fixed with 3.7% formaldehyde, washed in PBS,
and then incubated in PBS/0.2%Triton X-100 containingDAPI
for 5 min. Cells were then washed in PBS and a coverslip
applied using ProLong Gold antifade mounting medium
(Thermo Fisher Scientific). Cells were analyzed by using fluo-
rescence microscopy and the percentage of prophase-like cells
counted (i.e., cells with condensed chromatin but intact nuclear
membrane). The significance of the observed changes in PCC
was investigated byusing apaired t test,with values ofP, 0.05
denoted by an asterisk.
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RESULTS
MCPH1 isoforms are regulated in a cell
cycle–dependent manner
MCPH1 exists as 2 major isoforms, as schematically rep-
resented in Fig. 1A, withMCPH1-L (835 aa) consisting of 1
N-terminal and 2 C-terminal BRCT domains. MCPH1-S
(611 aa) lacks the pair of C-terminal BRCT domains. It is
currently not clear whether MCPH1 is regulated in a cell
cycle–dependent manner, with conflicting reports being
published.Ourgoalwas to investigatebothmajorMCPH1
isoforms, and we initially validated several commercial
antibodies by Western blotting of control and MCPH1-
depleted cells. Only 1 antibody was identified that was
able to robustly detect both MCPH1 isoforms in our ex-
perimental conditions. As shown in Fig. 1B (left-hand
panel), the antibody from Proteintech detected 2 bands at
the predicted MW for MCPH1-L and MCPH1-S in cell
extracts, with both bands lost in cells transfected with
MCPH1 siRNA. This antibody was also able to detect
immunoprecipitatedFLAG-taggedMCPH1-LandMCPH1-S,
which both alignedwell with the bands for endogenous
isoforms. In contrast, 2 other commercial antibodies (from
Abcam and Cell Signaling Technology) detected a strong
nonspecific signal at the approximate MW of MCPH1-L
(highlighted by an asterisk in Fig. 1B, middle and right-
hand panels). Importantly, this band was not decreased
afterMCPH1siRNA.Bothof these antibodieswereable to
detect MCPH1-S.
To investigate whetherMCPH1 protein levels changed
through the cell cycle,HeLa cellswere synchronized inG1
by using L-mimosine or in G2 by using RO3306 (a CDK1
inhibitor). After release into fresh medium and progres-
sion through the cell cycle, MCPH1 isoforms were ana-
lyzed at specific time points postrelease using Western
blotting.As shown inFig. 1C (left-handpanel), the levels of
Figure 1. MCPH1 isoforms are
regulated in a cell cycle–
dependent manner. A) Schematic
diagram showing the domain
structure and molecular mass of
MCPH1-L and MCPH1-S. B)
U2OS cells were transfected with
control siRNA or siRNA targeting
MCPH1 for 48 h before Western
blotting with the indicated com-
mercial antibodies. In the left-
hand panel, samples of purified
FLAG–MCPH1-L and FLAG–
MCPH1-S were included for com-
parison with endogenous MCPH1
protein bands. “L” and “S” in-
dicate bands corresponding to the
long and short MCPH1 isoforms,
respectively. C) HeLa cells were
synchronized in G1 with 500 mM
L-mimosine (20 h) or in G2 with
9 mM RO3306 (20 h) before
release into fresh medium for
the indicated time points and
Western blot analysis.
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MCPH1-L and MCPH1-S were both decreased after syn-
chronization in G1 (compare mimosine-treated cells in
lane2withasynchronouscells in lane1).After release from
theG1block, the levels of bothMCPH1isoformsgradually
increased as cells progressed toward/through the S phase
and towardG2/mitosis (as shownby the increase in cyclin
B and increased phosphorylation of histone H3 serine 10
after 9 h release). After release from a G2 block (Fig. 1C,
right-hand panel), cells rapidly entered mitosis (marked
increase in histone H3 serine 10 phosphorylation 1.5 h
post-release). At this same time point, MCPH1-L and
MCPH1-S both underwent a gel mobility shift, consistent
with protein phosphorylation (phosphatase treatment of
cell extracts eliminated thismobilityshift;datanot shown).
At 4 h post-release, levels of MCPH1-L and MCPH1-S
were both decreased, before beginning to increase after 6
and9h. These data suggest that bothMCPH1 isoforms are
regulated in a cell cycle–dependent manner, with phos-
phorylationduringmitosis anddecreasedprotein levels as
cells exit mitosis and enter the G1 phase of the cell cycle.
MCPH1 isoforms are phosphorylated
during mitosis
Figure 1C shows that as cells are released from the G2
block and enter mitosis, bothMCPH1 isoforms undergo a
gel mobility shift, consistent with protein phosphoryla-
tion. The mobility shift was reversed by l phosphatase
treatment of mitotic cell extracts (data not shown). To
further investigate the potential regulation of MCPH1
isoforms during mitosis, a nocodazole time-course treat-
ment was performed to synchronize cells in prom-
etaphase. Nocodazole disrupts mitotic spindles and
Figure 2. MCPH1 isoforms are phosphorylated during mitosis. A) U2OS cells were treated with 100 ng/ml nocodazole for the
indicated time points before Western blot analysis. Asynchronous cells (Asy) were also analyzed. B) U2OS cells were synchronized
in prometaphase by treatment with 100 ng/ml nocodazole (20 h). RO3306 (9 mM) was then added to the culture medium for the
indicated time points before Western blot analysis. C) U2OS cells were treated with nocodazole (100 ng/ml) for 20 h beforeWestern blot
analysis. In the right-hand panel, nocodazole-treated cells were lysed in native lysis buffer before addition (or not) of l-phosphatase for
20 min at 30°C. Samples were then analyzed by using Western blotting. D) Samples from B were reanalyzed by Western blotting to
allow comparison between 2 different MCPH1 antibodies (Cell Signaling Technology/CST vs. Proteintech). Aby, antibody.
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activates the spindle assembly checkpoint,whichprevents
progression to anaphase via inhibition of the APC/C. As
shown in Fig. 2A, MCPH1-L andMCPH1-S both undergo
a gelmobility shift as cells are blocked inmitosis, aswell as
an increase in protein abundance. The MCPH1 mobility
shift correlated well with the activation of CDK1, as in-
dicated by hypophosphorylation of CDK1 Tyr15. Similar
results were obtained with Taxol (MilliporeSigma) (data
not shown). CDK1 is highly active in nocodazole-treated
cells, and we used a specific CDK1 inhibitor (RO3306) to
investigate whether the observed MCPH1 phosphoryla-
tion was CDK1 dependent. As shown in Fig. 2B, addition
of RO3306 to nocodazole-treated cells caused a rapid loss
(apparent at 10min) of the slowermigrating band (i.e., loss
of phosphorylated form) of MCPH1-L and MCPH1-S. To
confirm CDK1 inhibition by RO3306, extracts were ana-
lyzed by using themitotic (phospho) protein monoclonal-
2 antibody,which recognizesmultipleCDK1 target proteins
phosphorylated in mitosis. Consistent with this finding, a
very strongsignalwasobservedafternocodazole treatment,
whichwas lost after CDK1 inhibition. At longer time points
after RO3306 treatment, MCPH1 levels decrease (data not
shown).
Similar studieswerealsoperformedbyusingadifferent
commercial antibody (from Cell Signaling Technology/
CST), which detects only MCPH1-S under our experi-
mental conditions. As shown in Fig. 2C, nocodazole
treatment caused an apparent decrease in MCPH1-S.
However, this effect was reversed by phosphatase treat-
ment of cell extracts, strongly suggesting that the antibody
recognition of MCPH1-S is being adversely affected by
phosphorylation. To further investigate this theory, we
reanalyzed the samples fromFig. 2B and compared results
with findings with the Proteintech antibody. The Cell
Signaling Technology antibody exhibited decreased rec-
ognitionofMCPH1-S innocodazole-treated cells (Fig. 2D),
which was rapidly reversed by treatment with the CDK1
inhibitor (i.e., as MCPH1 is being dephosphorylated).
Given that this change occurs within 10 min, it is very
unlikely to be due to an actual change in protein abun-
dance.Alongwith thedata in Fig. 2C,we conclude that the
Cell Signaling Technology antibody recognizes an epitope
withinMCPH1 that is phosphorylated duringmitosis and
this action impedes antibody binding.
Given themarked gel migration shift inMCPH1-L and
MCPH1-S after nocodazole, it is likely that MCPH1 is
heavily phosphorylated. To identify sites of phosphory-
lation,GFP–MCPH1-Lwas purified frommitotic cells and
analyzed by using mass spectrometry. Multiple phos-
phorylated peptides were identified, as summarized in
Table 1. Seven of these have been published previously,
and 4 were novel. CDK1 phosphorylates the minimal
consensus sequence S/T-P. Several of the identified sites
conform to this sequence, although additional studieswill
be required to verify MCPH1 sites that are directly phos-
phorylated by CDK1. Interestingly, 2 of the new sites
(Thr754 and Ser769) are within/near a potential D-Box
degron site and were investigated further later in this
study.
Together, thesedata show thatMCPH1-LandMCPH1-
S are phosphorylated in a CDK1-dependent manner dur-
ing mitosis.
MCPH1 isoforms are regulated by APC/C–CDH1
The accumulation of MCPH1 isoforms after cells are
blocked in prometaphase (Fig. 2A) and the decrease in
MCPH1 protein levels as cells exit mitosis (Fig. 1C) are
consistent with MCPH1 being a target of the APC/C
complex. To verify this theory, cells were released from a
nocodazoleblockandMCPH1 isoformsanalyzedbyusing
Western blotting. As shown in Fig. 3A, there was a loss of
both MCPH1-L and MCPH1-S 2–5 h after nocodazole re-
lease, which was blocked by treatment of cells with an
APC/C inhibitor (ProTAME). To further verify the role of
APC/C in MCPH1 regulation, a protein half-life study
was performed. Cycloheximide treatment of asynchro-
nous cells caused a time-dependent decrease inMCPH1-L
and MCPH1-S (Fig. 3B). In contrast, cycloheximide treat-
ment of cells synchronized in mitosis (by nocodazole
treatment) showed no decrease in the levels of either
MCPH1 isoform. Importantly, APC/C is inhibited in
nocodazole-treated cells due to activation of the spindle
TABLE 1. Phosphorylation sites identified in GFP–MCPH1-L from nocodazole-treated cells
Peptide Amino acid Previously published
TFTTQLVDMGAK T27 No
KLEGSINDIK S254 Yes
ANNIHSSPSFTHLDK S276 Yes
ANNIHSSPSFTHLDK S277 Yes
ANNIHSSPSFTHLDK S279 Yes
YRLSPTLSSTK S333 Yes
YSENLPPESQLPSSPAQLSCR S437 Yes
YSENLPPESQLPSSPAQLSCR S438 Yes
GTLFADQPVMFVSPASSPPVAK T754 No
GTLFADQPVMFVSPASSPPVAK S769 No
QASIVIGPYSGK S801 No
HEK293 cells were transfected with GFP–MCPH1-L for 24 h before nocodazole treatment (100 ng/
ml, 20 h). GFP–MCPH1 was purified from cells after mitotic shake-off and digested with trypsin/pronase.
Peptides were analyzed by mass spectrometry using a Sciex TripleTOF 5600. The phosphorylated pep-
tides are listed, with the site of phosphorylation underlined.
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assembly checkpoint. APC/C is activated by binding to
either CDC20 (promoting metaphase–anaphase transi-
tion) or CDH1 (promoting mitotic exit/G1 progression)
activator proteins. The kinetics of MCPH1 isoform deg-
radation are consistentwith APC/C–CDH1 activity. To
investigate this theory, CDH1 or CDC20 were overex-
pressed in cells and levels of MCPH1 investigated. As
shown in Fig. 3C, CDH1 caused a marked decrease in
both MCPH1-L and MCPH1-S, whereas CDC20 did
not. To further validate these findings, CDH1 was de-
pleted from cells using siRNA, causing a marked in-
crease in both MCPH1 isoforms (Fig. 3D). Together,
these studies show that MCPH1-L and MCPH1-S are
both degraded upon mitotic exit in an APC/C–CDH1–
dependent manner.
Characterization of theMCPH1–CDH1 interaction
We next investigated the potential interaction between
MCPH1 and CDH1. Given that CDH1 targets MCPH1 for
degradation in cells,we chose touse apull-downapproach
for these studies, rather than coexpression/purification of
both proteins. HEK293 cells were transfected with GFP
control oroneof theGFP-taggedconstructsdepicted inFig.
4A. GFP/GFP–MCPH1was thenpurified fromcells before
incubation with a FLAG–CDH1 cell extract. The potential
interaction between MCPH1 and CDH1 was then in-
vestigated by usingWestern blotting. As shown in Fig. 4B,
both MCPH1-L and MCPH1-S were able to bind CDH1,
whereas GFP and MCPH1 1–391 were not. These data
would suggest that a region of MCPH1 between 391 and
611 is important for the interaction with CDH1. CDH1
generally recognizes target proteins viaD-Box or KEN-Box
degron sequences. Analysis of the MCPH1 amino acid se-
quence revealed several potential degron sequences, in-
cluding a potential KEN-Box from 599 to 601. Each of the
KEN-box residues were mutated to alanine (KENmut) in
MCPH1-L and MCPH1-S and the CDH1 pull-down per-
formed. Interestingly, mutation of the KEN-Box signifi-
cantly reduced the binding of both MCPH1 isoforms to
CDH1 (Fig. 4C).
We also investigated the regions of CDH1 that were
important for binding toMCPH1,withCDH1containing
several WD40 domains that mediate protein–protein
interactions. The FLAG-tagged CDH1 constructs depicted
in Fig. 4D were incubated with purified GFP–MCPH1-L
Figure 3. MCPH1 isoforms are regulated by APC/C–CDH1. A) A549 cells were treated with 100 ng/ml nocodazole for 20 h
before release into fresh culture medium for the indicated time points. ProTAME (12 mM) was also included in one 5 h release
sample before Western blot analysis. B) Asynchronous and nocodazole-synchronized cells were treated with 50 mg/ml
cycloheximide (CHX) for the indicated time points to block protein synthesis before Western blotting. C) A549 cells were
transfected with FLAG empty vector, FLAG–CDH1, or FLAG–CDC20 for 48 h before Western blot analysis. D) A549 cells were
transfected with control siRNA or CDH1 siRNA for 72 h before Western blot analysis.
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before Western blotting. As shown in Fig. 4E, loss of the
extreme C-terminal WD40 domain markedly reduced
the interaction between MCPH1-L and CDH1.
Together, these data suggest that the KEN-Box in both
MCPH1 isoforms contributes to CDH1 binding and that
the seventh WD40 domain in CDH1 is important for
binding to MCPH1.
Isoform-specific regulation of MCPH1
by APC/C–CDH1
APC/C–CDH1 target proteins generally contain either
D-Box or KEN-Box degron sequences. Analysis of the
MCPH1 amino acid sequence revealed 4 potential
D-Boxes and 1 potential KEN-Box. Given that we have
shown that bothMCPH1-L andMCPH1-S bind CDH1 in
aKEN-Box–dependentmanner,wehypothesized that the
CDH1-dependent degradation of both isoformswould be
similarly reliant on this KEN-Box. We established an ex-
perimental system that allowed cotransfection of GFP–
MCPH1with either FLAGemptyvector or FLAG–CDH1.
We used an inducible GFP–MCPH1 plasmid to control
MCPH1 expression and showed that cotransfection with
FLAG–CDH1 caused amarked decrease inGFP–MCPH1
comparedwith cotransfectionwith FLAGvector (Fig. 5A).
We validated this system further by showing that both
GFP–MCPH1-L andGFP–MCPH1-Swere decreased by
FLAG–CDH1 but not by FLAG–CDC20, in agreement
with our data for endogenous MCPH1 (Fig. 5B). Ini-
tially, we mutated the KEN-Box (KENmut) in MCPH1-L
Figure 4. Characterization of the
MCPH1–CDH1 interaction. A)
Schematic diagram of MCPH1
fragments to be used in CDH1
pull-down studies. The sites of
potential D-Box and KEN-Box
degron sequences are indicated.
B) GFP or GFP–MCPH1 variants
were transfected into HEK293 cells
for 24 h before purification and
incubation with FLAG–CDH1 cell
extracts (from transfected HEK293
cells). The ability of CDH1 to bind
MCPH1-L was investigated by us-
ing Western blotting. C) The KEN-
Box sequence was mutated to
“AAA” in GFP–MCPH1-L and
GFP–MCPH1-S before performing
the CDH1 pull-down experiment
as described in B. D) Schematic
diagram of CDH1 fragments to be
used in pull-down studies with
GFP–MCPH1-L. E) FLAG–CDH1
(or CDH1 fragment) pull-down
was performed as in B.
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and MCPH1-S and cotransfected with FLAG–CDH1.
Surprisingly, we found thatMCPH1-L–KENmut was still
degraded by CDH1 (Fig. 5C, left-hand panel), whereas
MCPH1-S–KENmut was not (Fig. 5C, right-hand panel).
This finding suggests that the 2 major isoforms of
MCPH1 are regulated in different ways by APC/C–
CDH1. As we were performing these studies, a paper
was published suggesting that D-Box4 was important
for MCPH1-L degradation (23). In agreement, we found
that mutation of this D-Box (RxxL to AxxA, DB4mut)
blocked the CDH1-dependent degradation of MCPH1-
L. To verify our findings of MCPH1 isoform-specific
regulation, we performed cotransfection studies with
either MCPH1-L, MCPH1-L–DB4mut, MCPH1-S, or
MCPH1-S–KENmut with either FLAG, FLAG–CDH1, or
FLAG–CDC20. As shown in Fig. 5D, the CDH1-
dependent degradation of MCPH1-L required D-Box4,
whereas theCDH1-dependent degradation ofMCPH1-S
required the KEN-Box; CDC20 did not cause the degra-
dation of any MCPH1 variants.
D-Box4 phosphorylation is not involved in
CDH1-mediated regulation of MCPH1
Themass spectrometry analysis of purifiedGFP–MCPH1-
L identified several novel sites of phosphorylation. In-
terestingly, one of these sites (Thr754) was within D-Box4,
the degron sequence required for the degradation of
MCPH1-L. Another novel site (Ser769) was also identified
a few amino acids downstream of D-Box4 (indicated
in Fig. 6A). We therefore investigated whether phos-
phorylation of Thr754 or Ser769 regulated either the
MCPH1-L–CDH1 interaction or the CDH1-mediated
degradation of MCPH1-L. Phosphomutant (T754A
and S769A) and phosphomimetic (T753E and S769E)
variants ofGFP–MCPH1-Lwereproducedandutilized in
Figure 5. Isoform-specific regu-
lation of MCPH1 by APC/C–
CDH1. A) HeLa Tet-On cells
were cotransfected with GFP–
MCPH1-L and either FLAG
empty vector or FLAG–CDH1.
GFP–MCPH1-L expression was
induced by the addition of
tetracycline 10 ng/ml. After
24 h, cells were lysed and
samples analyzed by using West-
ern blotting. B) HeLa Tet-On
cells were cotransfected with
GFP–MCPH1-L or GFP–MCPH1-
S, along with either FLAG empty
vector or FLAG–CDC20 or FLAG–
CDH1. GFP–MCPH1 expression
was induced and samples pro-
cessed as in A. C, D) HeLa Tet-
ON cells were cotransfected with
the indicated plasmids and pro-
cessed as in A.
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pull-down experiments with FLAG–CDH1. As shown in
Fig. 6B,mutation of neither Thr754nor Ser769 affected the
interaction between MCPH1-L and CDH1. In addition, in
coexpressionstudieswithphosphomutants/phosphomimetics
cotransfected with FLAG or FLAG–CDH1, all variants of
MCPH1-Lwere degraded byCDH1 (Fig. 6C). Together, these
data suggest that Thr754 and Ser769 phosphorylation are not
involved in the MCPH1-L–CDH1 interaction or the CDH1-
mediated regulation ofMCPH1-L.
MCPH1-L KEN-Box or D-Box4 are not involved
in the chromatin condensation function
of MCPH1
A striking phenotype of MCPH1-deficient cells is the
increased number of cells with prematurely condensed
chromatin, often described as PLCs in the literature.
Little is known about how this particular function of
MCPH1 is regulated. Using siRNA, we efficiently de-
pleted MCPH1 from U2OS cells and investigated the
proportion of PLCs (indicated by the white arrow in
Fig. 7A) using fluorescence microscopy. Consistent
with previous data, we found that control cells had
,1% PLCs, whereas cells lacking MCPH1 had .12%
PLCs. Importantly, GFP–MCPH1-L (with silent muta-
tions in the siRNA target sequence)was able to partially
correct this phenotype (Fig. 7B). The lack of full
complementation is likely due to the transfection effi-
ciency of GFP–MCPH1 being ;70%. The lack of full
complementation could also be due to the absence of
endogenousMCPH1-S in theMCPH1 siRNA cells, with
this isoform also able to correct the PLC phenotype in
MCPH1-deficient cells (19). We next used the MCPH1-
L–KENmut and MCPH1L–DB4mut in complementation
studies. As shown in Fig. 7C, all variants of MCPH1-L
corrected the PCC phenotype to similar extents. To-
gether, these data suggest that the KEN-Box and D-Box
4 (involved in the interaction with CDH1 and CDH1-
dependent degradation, respectively) do not contribute
to the chromatin condensation function of MCPH1.
DISCUSSION
MCPH1 helps coordinate and control key events associ-
ated with mitotic entry, including CDK1 activation and
chromosome condensation. In addition, MCPH1 func-
tions as a tumor suppressor with roles in DNA damage
repair, checkpoint activation, and apoptosis. Despite these
roles, there is currently little information on howMCPH1
is regulated at the protein level. We found that both
MCPH1 isoforms are phosphorylated during mitosis in a
CDK1-dependent manner, followed by isoform-specific
regulation by APC/C–CDH1.
Figure 6. D-Box4 phosphoryla-
tion is not involved in CDH1-
mediated regulation of MCPH1.
A) Schematic diagram of MCPH1-
L showing the positions of D-Box4
and the novel phosphorylation
site in or near this degron se-
quence. B) GFP or GFP–MCPH1
variants were transfected into
HEK293 cells for 24 h before
purification and incubation with
FLAG–CDH1 cell extracts (from
transfected HEK293 cells). The
ability of CDH1 to bind MCPH1
was investigated by using Western
blotting. C) HeLa Tet-On cells
were cotransfected with GFP–
MCPH1-L (or the indicated
phosphomutants/phosphomi-
metics) and either FLAG empty
vector or FLAG–CDH1. GFP–
MCPH1-L expression was induced
by the addition of tetracycline
10 ng/ml. After 24 h, cells were
lysed and samples analyzed by
using Western blotting.
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To date, 14 genes have been shown to cause primary
microcephaly when mutated. Interestingly, each of these
genes has some role in mitotic regulation, but the PCC
phenotype isunique toMCPH1(24).Cell-free studieshave
suggested that MCPH1 is able to block the binding of
condensin II to mitotic chromatin, helping maintain in-
terphase chromatin in a noncondensed state (8). It follows
that in a normal cell cycle, there must be a regulatory
mechanism that alleviates the inhibitory effect of MCPH1
on condensin II, promoting chromosome condensation in
mitosis. Thismechanismdoes not involve the degradation
ofMCPH1, aswe showthatMCPH1 ispresent throughout
mitosis and actually accumulates as cells are blocked in
prometaphase, where chromatin is highly condensed. It is
more likely that a rapid posttranslational modification of
MCPH1 (or condensin II subunits) acts as a switch to help
regulate MCPH1/condensin II–mediated chromatin con-
densation. Interestingly, we show that MCPH1 is phos-
phorylated in a CDK1-dependent manner in cells treated
with nocodazole, and this phosphorylation is rapidly lost
(within 10 min) as cells are released from the prom-
etaphase block. It is tempting to speculate that mitotic
phosphorylation of MCPH1 helps to maintain chromatin
condensation by alleviating MCPH1-mediated inhibition
of condensin II, and this scenario is reversed asMCPH1 is
dephosphorylatedduringmitotic exit, allowingchromatin
decondensation. In agreement, studies have shown that
cells lacking MCPH1 have delayed chromosome decon-
densation at mitotic exit (5).
A recent study suggested that MCPH1-deficient cells
undergo PCC in the G2 phase in a process dependent on
CDK1 activity (9). This study showed that treatment with
the CDK1 inhibitor (RO3306) for 4 or 7 h reduced the
percentage of PLCs in MCPH1-deficient cell cultures by
;10%.Other studies have also reported early activation of
CDK1 (hypophosphorylation) in human and mouse cells
lackingMCPH1 (3, 10). Although it is tempting to support
a model whereby cells lacking MCPH1 undergo pre-
mature CDK1 activation, and this process drives con-
densin II–mediated chromosome condensation, such a
Figure 7.MCPH1-L KEN-Box or D-Box4 are not involved in the chromatin condensation function of MCPH1. A) U2OS cells were
cotransfected with control siRNA (siCON) or MCPH1 siRNA (siMCPH1) along with either GFP empty vector or siRNA-resistant
GFP–MCPH1-L. After 72 h, cells were fixed, stained with DAPI, and analyzed by fluorescence microscopy to identify PLCs that are
characteristic of the PCC phenotype (indicated by white arrows). B) The percentage of PLCs was quantified after analyzing .300
cells. C) The studies outlined in A and B were repeated with the D-Box4 and KEN-Box mutant variants of MCPH1-L. The
significance of the observed changes in PCC were investigated by using a Student’s paired t test. *P , 0.05.
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model is difficult to reconcile with data showing lack of
histoneH3Ser10phosphorylation inPCCcells (3, 4), given
that activation of CDK1 is the key event that triggers mi-
totic entry. It is clear that MCPH1 contributes to the reg-
ulation of chromosome condensation andCDK1 activation;
how these events are coordinated and controlled, however,
remains to be fully elucidated. Tounderstand this process, it
is essential to identify and characterize the cellular mecha-
nisms that regulate the function of MCPH1 isoforms
throughout the cell cycle.
There are limited studies investigating cell cycle–
dependent regulation of MCPH1. Gavvovidis et al. (19)
reported fluctuations in both MCPH1 isoforms at the
transcript level, with MCPH1-L mRNA decreased from
themid-S phase to the G2 phase and decreasedMCPH1-S
mRNA in the early S phase before increasing in the late S/
G2 phase. At the protein level, initial studies suggested
that human MCPH1 was not regulated in a cell cycle–
dependent manner, with no apparent change in protein
levels or gel migration pattern in cell synchronization
studies (17, 20). However, both studies used commercial
MCPH1 antibodies (Ab2612, Abcam; and 4120, Cell Sig-
nalingTechnology) that, inourvalidation studies, strongly
recognized a nonspecific band at the approximate molec-
ular mass of MCPH1-L. Hainline et al. (20) showed that
DrosophilaMCPH1wasdegradedbyAPC/C–CDH1,but
this effect was dependent on a D-Box present in an
N-terminal extension of Drosophila MCPH1 that is com-
pletely absent in the human protein. This same study
suggested that human MCPH1 was not degraded after
release of HeLa cells from a nocodazole block, using the
Cell Signaling Technology antibody. A recent study sug-
gested that MCPH1 levels decreased in mitosis, before
cyclin B1 degradation (23). Given that cyclin B1 is de-
graded by APC/C–CDC20 (activated before APC/C–
CDH1), this observation would be inconsistent with
MCPH1 being a target of CDH1. It is likely that the ap-
parent decrease in MCPH1 in those studies was due to
MCPH1 phosphorylation in mitosis and subsequent
blocking of antibody binding, as shown in our validation
studies using the MCPH1 antibody from Cell Signaling
Technology. Unfortunately, we were unable to obtain
precise information regarding the epitope used to gener-
ate this particular antibody, which could have allowed
identification of the specific phosphorylation sites that
block antibody binding. Cell Signaling Technology stated
that this information was proprietary, although they did
confirm that a “peptide surrounding Ser433 of human
MCPH1 was used.” (personal communication). Our an-
tibody testing results could be highly relevant when
assessing the conclusions of some previously published
data. In particular, care should be taken to ensure that the
correct isoform of MCPH1 is being detected, and consid-
eration should also be given to the potential effect of
phosphorylation when using the Cell Signaling Technol-
ogy antibody.
We found that both MCPH1 isoforms are degraded by
APC/C–CDH1 after cells exit mitosis. CDH1 recognizes
many of its target proteins via D-Box or KEN-Box degron
sequences. We have described 2 such sequences in
MCPH1-L that appear to be functionally relevant. The first
sequence is a C-terminal D-Box that is necessary for
CDH1-dependent degradation of MCPH1-L, in agree-
ment with a recent study (23). The second is a KEN-Box
sequence, mutation of which markedly reduced the in-
teraction betweenMCPH1andCDH1but hadno effect on
CDH1-mediated degradation of MCPH1-L. It will be in-
teresting to study the functional significance of this KEN-
Box sequence in the large MCPH1 isoform. It is possible
that MCPH1-L is also able to bind (via KEN-Box) and
regulate the activity of APC/C–CDH1, or help recruit
specific substrates via its 3 BRCT domains, whichmediate
protein–protein interactions. Another BRCT domain–
containingprotein, 53BP1,was recently shown tobebotha
target and regulator ofAPC/C–CDC20 (25). Interestingly,
we have also shown thatMCPH1-L is able to interactwith
CDC20 (data not shown), althoughCDC20wasnot able to
cause degradation of MCPH1-L or MCPH1-S.
In addition to controlling mitotic exit and G1 progres-
sion, APC/C–CDH1 contributes to DNA damage re-
sponse pathways by degrading various proteins after
ionizing radiation and UV radiation (26–28). After ioniz-
ing radiation, the resultant DNAdouble-strand breaks are
repaired by either HRR (only in S/G2 phases) or non-
homologous end joining (cell cycle independent). A recent
study showed that CDH1 contributes to the choice of
double-strand break repair pathway, promoting HRR by
targeting the deubiquitinating enzyme USP1, which in
turn allows recruitment of the pro-HRR BRCA1 to DNA
double-strand breaks (29). Given that MCPH1 also posi-
tively contributes to HRR, it will be interesting to in-
vestigate whether the MCPH1-L KEN-Box (and thus
MCPH1-L–CDH1 interaction) regulates this pathway. In
contrast toMCPH1-L, theKEN-Box is required for CDH1-
mediateddegradation ofMCPH1-S, showing thatMCPH1
isdegradedinanisoform-specificmannerbyAPC/C–CDH1.
MCPH1 has an important role in brain development
and has several hallmarks of a tumor suppressor protein,
although the regulatorymechanisms that controlMCPH1
function are poorly understood.We have shown that both
MCPH1 isoforms are phosphorylated during mitosis in a
CDK1-dependent manner and then regulated by APC/
C–CDH1 in an isoform-specific manner. As well as clari-
fying how MCPH1 is regulated during the cell cycle, we
are hopeful that the other regulatory mechanisms that we
have identified, along with our observations with certain
MCPH1 antibodies, will aid future research related to the
important cellular roles of MCPH1.
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